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Ceftriaxone would seem to fulfil many of the criteria f'or single dose treatment of uncomplicated gonorrhoea. Its plasma half' life is 6%/ to 8'/! hours, whereas other cephalosporins have half lives of 45 minutes to 2½/ hours.' ' Its bioavailability is 100%c, when given intramuscularly, 40%(1 being excreted in bile and 60% in urine.' 2 Probenecid has no effect on its excretion.' It has an excellent safety record' 2 and is well tolerated by patients.3 '5 In vitro its potency for both penicillinase producing
Nei.sseri(a -onor,lohoceae (PPNG) and non-PPNG strains exceeds that of all other cephalosporins to date and of other antibiotics witlh which it has been compared.6x
In vivo almost all the published trials to date have shown 100%lc cure rates for uncomplicated urethral, cervical, and rectal gonorrhoea caused by both PPNG and non-PPNG strains, using dosages as low as 125 mg ceftriaxone.'' ")I We report our experience witlh cet'triaxone, comparing it with penicillin in an observer blind trial.
Address for reprints: Dr C A Dixon, Perth and Amberley House Clinics, General Hospital, Nottingham NGI 6HA Accepted for publication 24 July 1985 Patients studied attended the clinics for sexually transmitted diseases at Nottingham and Lincoln and gave informed verbal consent.
To be admitted into the trial men had to have uncomplicated urethral or rectal gonorrhoea diagnosed by the presence of Gram negative intracellular diplococci (GNICD) in smears from those sites. Swabs were taken from the urethra in heterosexual patients and from the urethra and rectum in homosexuals, and were transported in Amies' medium. N gonorrhloeae was isolated on modified New York City (MNYC) medium'7 with added antiboitics for non-urethral specimens. Minimum inhibitory concentrations (MICs) of penicillin and ceftriaxone f'or the isolates were measured by agar incorporation in MNYC medium, using reference strains IRS3 and IRS5 as controls. Strains isolated at the Public Health Laboratory, Lincoln, were sent to Nottingham for ceftriaxone testing (by courtesv of the Director, Dr J G Wallace). Patients in whom the initial cultures for N -onorrhioeae were negative were subsequently excluded f'roint the trial. Patients were excluded if they had received antibiotics in the previous 10 All patients were asked to attend again two to three days after treatment and after nine days and 16 days; they were asked to abstain from sexual intercourse during this period. At the first follow up visit they were asked about symptoms, sexual activitiy, and any side effects of their treatment. At each visit smears for microscopy and material for culture were taken from the same sites as initially.
In women, infections with other organisms, such as Candi(ta albicans. Trichomonas vagina/is, and ChlamY (ia taclhomatis were treated 10 days after giving the trial drug. In men culture for C traclioniatis was not undertaken routinely, but postgonococcal urethritis (PGU), which was defined as 10 
Discussion
Ceftriaxone has shown consistently high success rates in treating uncomplicated urogenital gonorrhoea in all reports published to date; the doses used compare, in many cases, with those used to treat the gonococcus with penicillin in the early days of antibiotic treatment. Table III summarises those trial results where ceftriaxone has been 100% successful in doses of 125 mg to 500 mg. At the much lowerdoses of 32 5 mg and 62 5 mg the cure rate was still 100% for urethral infections with PPNG strains;" in non-PPNG urethral infections the cure rates were 96-2% with 62 5 mg, 95% Because of the low doses used, it was possible to use very small amounts of lignocaine diluent, thus minimising pain at the injection site without affecting the bioavailability of the drug.22 Though in our trial we used 2 ml lignocaine for 250 mg ceftriaxone and 4 ml for the 500 mg dose, other trials have used half these amounts, with only 0 5 ml lignocaine for 125 mg ceftriaxone, and in some cases the injections were given into the deltoid muscle almost painlessly.4 t0 20 In our trial the incidence of local pain was less with the lower dose of ceftriaxone.
We did not perform tests of liver and kidney function or full blood counts before and after treatment, but in the trials where these have been undertaken no harmful effects were noted.3 5 t3 20 21 It is recognised that cephalosporins do not cure chlamydial infections, and other trials have shown no difference in the incidence of PGU after ceftriaxone and after spectinomycin3 or kanamycin. " In our trial a higher incidence of PGU was noted after ceftriaxone than after Bicillin.
Another infection that may coexist with gonorrhoea is early syphilis, and ceftriaxone has been shown to be effective in treating syphilis in rabbits,23 so 
